BEAT CAR T therapy
Pre-clinical- Indications
- Solid tumors
Company intelligence / Profile preview
Currus Biologics
Melbourne, Victoria, Australiacurrusbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Currus Biologics has demonstrated in preclinical models that its BEAT technology enhances CAR-T cell proliferation, persistence, trafficking to tumors, and immunological memory against additional antigens. No clinical results are available yet; the company remains in the preclinical development phase for its lead programs.[1][2][6]
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapiesTCR cell therapiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Currus Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Currus Biologics.